Paroxetine Controlled Release
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 18 (6), 355-364
- https://doi.org/10.2165/00023210-200418060-00003
Abstract
▴ A controlled-release (CR) formulation of the SSRI paroxetine has been developed. This CR formulation delays the release of paroxetine until the tablet has passed through the stomach; the drug is then released over 4–5 hours. ▴ In well designed placebo-controlled trials in patients with major depressive disorder (including a study in the elderly), social anxiety disorder or premenstrual dysphoric disorder (PMDD), paroxetine CR was consistently superior to placebo with regards to primary endpoints (i.e. mean Hamilton Rating Scale for Depression total score [major depressive disorder], Liebowitz social anxiety scale total score and Clinical Global Impressions-Global Improvement score [social anxiety disorder] and Visual Analogue Scale-Mood score [PMDD]). The duration of treatment was 12 weeks or, in PMDD, over three menstrual cycles (intermittent or continuous administration). ▴ Paroxetine CR also demonstrated efficacy in three well designed studies in patients with panic disorder with or without agoraphobia. ▴ Paroxetine CR was generally well tolerated in clinical trials, with an adverse-event profile typical of SSRIs, although recipients of paroxetine CR experienced significantly less nausea than recipients of immediate-release paroxetine in the first week of treatment.Keywords
This publication has 24 references indexed in Scilit:
- Premenstrual Dysphoric DisorderNew England Journal of Medicine, 2003
- Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With ParoxetineAmerican Journal of Psychiatry, 2002
- Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depressionThe British Journal of Psychiatry, 2002
- ParoxetineDrugs, 2002
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold DepressionsThe World Journal of Biological Psychiatry, 2002
- ParoxetineDrugs, 1998
- ParoxetineCNS Drugs, 1997
- A review of the psychomotor effects of paroxetineInternational Clinical Psychopharmacology, 1997
- Current advances and trends in the treatment of depressionTrends in Pharmacological Sciences, 1994
- ParoxetineDrugs, 1991